In severe leptospirosis with pulmonary involvement, eight desmopressin recipients died versus three controls, without a significant mortality difference.
In plain wordsIn severe leptospirosis with lung involvement, eight desmopressin recipients died versus three controls. Mortality did not differ significantly.
- Peptide
- Desmopressin
- Outcome
- No significant changeDeaths in intention-to-treat population
- Study
n: not reported in source
- Comparator
- Standard critical care alone
- Outcome group
- Mortality · Respiratory
- Studied dose
- Dose not stated
Measurements
- Deaths, all three groups
- 15 patients
- intention-to-treat
- Deaths, all three groups
- 22%
- intention-to-treat
- Deaths
- 8 patients
- desmopressin group
- Deaths
- 4 patients
- pulse dexamethasone group
- Deaths
- 3 patients
- critical care alone group
- P value
- 0.19
- deaths across the three groups
Source sentences
There were 15 deaths (22%), of which eight patients received desmopressin, four patients received pulse dexamethasone, and three patients received critical care alone (p 0.19).
3 context sentences(design, population, supporting numbers)
The mortality was not significantly different in the desmopressin group or pulse dexamethasone group compared to the control group in both intention-to-treat patients, and in patients with confirmed leptospirosis.
A prospective randomized controlled trial of desmopressin or high-dose (pulse) dexamethasone as adjunctive therapy in 68 patients with pulmonary involvement associated with severe leptospirosis was conducted between July 2003 and October 2006 at five hospitals in Thailand.
There were 23 patients in the desmopressin group, 22 in the pulse dexamethasone group, and 23 in a control group who received standard critical care alone.